Literature DB >> 22887854

Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stem-like cells via NF-κB-mediated MMP-9 upregulation.

Haixia Long1, Rongkai Xie, Tong Xiang, Zhongquan Zhao, Sheng Lin, Zhiqing Liang, Zhengtang Chen, Bo Zhu.   

Abstract

The concept of cancer stem cells (CSCs) proposes that solely CSCs are capable of generating tumor metastases. However, how CSCs maintain their invasion and migration abilities, the most important properties of metastatic cells, still remains elusive. Here we used CD133 to mark a specific population from human ovarian cancer cell line and ovarian cancer tissue and determined its hyperactivity in migration and invasion. Therefore, we labeled this population as cancer stem-like cells (CSLCs). In comparison to CD133- non-CSLCs, chemokine CCL5 and its receptors, CCR1, CCR3, and CCR5, were consistently upregulated in CSLCs, and most importantly, blocking of CCL5, CCR1, or CCR3 effectively inhibits the invasive capacity of CSLCs. Mechanistically, we identified that this enhanced invasiveness is mediated through nuclear factor κB (NF-κB) activation and the consequently elevated MMP9 secretion. Our results suggested that the autocrine activation of CCR1 and CCR3 by CCL5 represents one of major mechanisms underlying the metastatic property of ovarian CSLCs.
Copyright © 2012 AlphaMed Press.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22887854     DOI: 10.1002/stem.1194

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  89 in total

Review 1.  NF-κB signaling in cancer stem cells: a promising therapeutic target?

Authors:  K Vazquez-Santillan; J Melendez-Zajgla; L Jimenez-Hernandez; G Martínez-Ruiz; V Maldonado
Journal:  Cell Oncol (Dordr)       Date:  2015-08-29       Impact factor: 6.730

2.  CARF (Collaborator of ARF) overexpression in p53-deficient cells promotes carcinogenesis.

Authors:  Rajkumar S Kalra; Caroline T Cheung; Anupama Chaudhary; Jay Prakash; Sunil C Kaul; Renu Wadhwa
Journal:  Mol Oncol       Date:  2015-08-04       Impact factor: 6.603

3.  Participation of Tumor-Associated Myeloid Cells in Progression of Amelanotic Melanoma (RMM Tumor Line) in F344 Rats, with Particular Reference to MHC Class II- and CD163-Expressing Cells.

Authors:  A Bondoc; H M Golbar; M Pervin; C Katou-Ichikawa; M Tanaka; T Izawa; M Kuwamura; J Yamate
Journal:  Cancer Microenviron       Date:  2017-06-16

4.  Effect of TRAF6 on the biological behavior of human lung adenocarcinoma cell.

Authors:  Lou Zhong; Fei Cao; Qingsheng You
Journal:  Tumour Biol       Date:  2012-10-04

Review 5.  Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Authors:  Mark A Feitelson; Alla Arzumanyan; Rob J Kulathinal; Stacy W Blain; Randall F Holcombe; Jamal Mahajna; Maria Marino; Maria L Martinez-Chantar; Roman Nawroth; Isidro Sanchez-Garcia; Dipali Sharma; Neeraj K Saxena; Neetu Singh; Panagiotis J Vlachostergios; Shanchun Guo; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Alan Bilsland; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; W Nicol Keith; Somaira Nowsheen
Journal:  Semin Cancer Biol       Date:  2015-04-17       Impact factor: 15.707

6.  Synthesis of 8-hydroxyquinoline derivatives as novel antitumor agents.

Authors:  Sau Hing Chan; Chung Hin Chui; Shun Wan Chan; Stanton Hon Lun Kok; Dessy Chan; Miriam Yuen Tung Tsoi; Polly Hang Mei Leung; Alfred King Yin Lam; Albert Sun Chi Chan; Kim Hung Lam; Johnny Cheuk On Tang
Journal:  ACS Med Chem Lett       Date:  2012-12-20       Impact factor: 4.345

Review 7.  Cancer stem cells: a potential target for cancer therapy.

Authors:  Hong Qiu; Xiaoguang Fang; Qi Luo; Gaoliang Ouyang
Journal:  Cell Mol Life Sci       Date:  2015-05-13       Impact factor: 9.261

8.  Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells.

Authors:  Y You; Y Li; M Li; M Lei; M Wu; Y Qu; Y Yuan; T Chen; H Jiang
Journal:  Clin Exp Immunol       Date:  2017-10-23       Impact factor: 4.330

Review 9.  CD133: a cancer stem cells marker, is used in colorectal cancers.

Authors:  Fei Ren; Wei-Qi Sheng; Xiang Du
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

10.  Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer.

Authors:  T Xiang; H Long; L He; X Han; K Lin; Z Liang; W Zhuo; R Xie; B Zhu
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.